-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, G7J0uoLYz4i1LmPMcL6BvcF1Gc1RsPNwrmAmkRmMYVXyXFGBEg2cdnvFNl3jtcxu GVOTALTkD9TurOG39/XRaw== 0001144204-10-043785.txt : 20100813 0001144204-10-043785.hdr.sgml : 20100813 20100813172154 ACCESSION NUMBER: 0001144204-10-043785 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20100813 DATE AS OF CHANGE: 20100813 GROUP MEMBERS: FELIX J. BAKER SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: GENOMIC HEALTH INC CENTRAL INDEX KEY: 0001131324 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 770552594 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-81275 FILM NUMBER: 101016281 BUSINESS ADDRESS: STREET 1: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-556-9300 MAIL ADDRESS: STREET 1: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BAKER JULIAN CENTRAL INDEX KEY: 0001087939 FILING VALUES: FORM TYPE: SC 13D/A MAIL ADDRESS: STREET 1: BAKER BROTHERS ADVISORS STREET 2: 667 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10021 SC 13D/A 1 v193919_sc13da.htm Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
SCHEDULE 13D
Under the Securities Exchange Act of 1934
 
(Amendment No. 6)
 
Genomic Health, Inc
(Name of Issuer)
     
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
     
 
37244C101
 
 
(CUSIP Number)
 
     
Leo Kirby
667 Madison Avenue, 21st Floor
New York, NY  10065
(212) 339-5633
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
     
 
August 12, 2010
 
 
(Date of Event which Requires Filing of this Statement)
 
     

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.  o
 
Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See Rule 13d-7 for other parties to whom copies are to be sent.
 
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
 
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 
Page 1 of 8 Pages


SCHEDULE 13D
 
CUSIP No.   37244C101      
 
 
Page   2   of   8   Pages
 

1
 
NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Julian C. Baker
 
2
 
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
 
(a)   o
(b)   o
 
3
 
SEC USE ONLY
 
4
 
SOURCE OF FUNDS (See Instructions)
WC
 
5
 
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
 
  o
6
 
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
 
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
 
7
 
SOLE VOTING POWER
41,250
 
8
 
SHARED VOTING POWER
6,510,937
 
9
 
SOLE DISPOSITIVE POWER
41,250
 
10
 
SHARED DISPOSITIVE POWER
6,510,937
 
11
 
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
6,552,187
 
12
 
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
 
  o
13
 
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
22.7%
 
14
 
TYPE OF REPORTING PERSON (See Instructions)
IN
 

Page 2 of 8 Pages


SCHEDULE 13D
 
CUSIP No.  37244C101      
 
 
Page   3   of   8    Pages
 

1
 
NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Felix J. Baker
 
2
 
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
 
(a)  o
(b)  o
 
3
 
SEC USE ONLY
 
4
 
SOURCE OF FUNDS (See Instructions)
WC
 
5
 
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
 
  o
6
 
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
 
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
 
7
 
SOLE VOTING POWER
0
 
8
 
SHARED VOTING POWER
6,510,937
 
9
 
SOLE DISPOSITIVE POWER
  0
 
10
 
SHARED DISPOSITIVE POWER
6,510,937
 
11
 
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
6,510,937
 
12
 
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
 
  o
13
 
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
22.6%
 
14
 
TYPE OF REPORTING PERSON (See Instructions)
IN
 
Page 3 of 8 Pages


This Amendment No. 6 to Schedule 13D is being filed by Julian C. Baker and Felix J. Baker (the “Reporting Persons”) to supplement the statements on Schedule 13D previously filed by them, as heretofore amended.  Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect.
 
Item 5.
Interest in Securities of the Issuer.
 
Set forth below is the aggregate number of shares of Common Stock held, including shares that maybe acquired upon exercise of Options as of the date hereof by each of the following, together with the percentage of outstanding shares of Common Stock that such number represents based upon 28,823,369 shares outstanding, as reported on the company’s SEC Form 10Q filed on August 9, 2010. Such percentage figures are calculated on the basis that the Options owned by the Reporting Persons are deemed exercised for shares of Common Stock but other outstanding Options are not deemed exercised.
 
Name
 
Number of Shares
   
Percent of Class
Outstanding
 
Baker Bros. Investments, L.P.
    173,897       0.6 %
Baker Bros. Investments II, L.P.
    20,287       0.1 %
667, L.P.
    1,253,653       4.4 %
Baker Brothers Life Sciences, L.P.
    4,570,896       15.8 %
14159, L.P.
    124,146       0.4 %
FBB Associates
    173,897       0.6 %
Baker/Tisch Investments, L.P.
    194,161       0.7 %
Julian C. Baker
    41,250       0.1 %
Total
    6,552,187       22.7 %

 
By virtue of their ownership of entities that have the power to control the investment decisions of the limited partnerships listed in the table above, Julian C. Baker and Felix J. Baker may each be deemed to be beneficial owners of shares owned by such entities and may be deemed to have shared power to vote or direct the vote of and shared power to dispose or direct the disposition of such securities.  Julian C. Baker and Felix J. Baker are also the sole partners of FBB Associates, a general partnership, and as such may be deemed to be beneficial owners of shares owned by FBB Associates and may be deemed to have shared power to vote or direct the vote and dispose or direct the disposition of those shares.
 
Julian C. Baker is a Director of the Company.
 
The following transactions in Common Stock were effected by the entities noted below during the sixty days preceding the filing of this statement. None of the reporting Persons has effected any other transactions in Common Stock during this period.
 
Page 4 of 8 Pages

 
                 
Name
Date
 
Number of
         
     
Shares
 
Transaction
 
Price / Share
 
                 
Baker Brothers Life Sciences, L.P.
8/6/2010
    10,556  
Purchase
    14.1823  
14159, L.P.
8/6/2010
    291  
Purchase
    14.1823  
Baker Brothers Life Sciences, L.P.
8/6/2010
    34,371  
Purchase
    14.1556  
14159, L.P.
8/6/2010
    949  
Purchase
    14.1556  
Baker Brothers Life Sciences, L.P.
8/9/2010
    46,260  
Purchase
    14.8042  
14159, L.P.
8/9/2010
    1,277  
Purchase
    14.8042  
Baker Brothers Life Sciences, L.P.
8/9/2010
    16,350  
Purchase
    14.8197  
14159, L.P.
8/9/2010
    451  
Purchase
    14.8197  
Baker Brothers Life Sciences, L.P.
8/10/2010
    37,242  
Purchase
    14.7896  
14159, L.P.
8/10/2010
    1,028  
Purchase
    14.7896  
Baker Brothers Life Sciences, L.P.
8/10/2010
    19,463  
Purchase
    14.6649  
14159, L.P.
8/10/2010
    537  
Purchase
    14.6649  
Baker Brothers Life Sciences, L.P.
8/11/2010
    18,893  
Purchase
    14.7418  
14159, L.P.
8/11/2010
    522  
Purchase
    14.7418  
Baker Brothers Life Sciences, L.P.
8/11/2010
    9,313  
Purchase
    14.7051  
14159, L.P.
8/11/2010
    257  
Purchase
    14.7051  
Baker Brothers Life Sciences, L.P.
8/12/2010
    12,294  
Purchase
    15.0119  
14159, L.P.
8/12/2010
    339  
Purchase
    15.0119  
Baker Brothers Life Sciences, L.P.
8/12/2010
    9,425  
Purchase
    14.9976  
14159, L.P.
8/12/2010
    260  
Purchase
    14.9976  
Baker Brothers Life Sciences, L.P.
8/12/2010
    8,577  
Purchase
    14.9389  
14159, L.P.
8/12/2010
    237  
Purchase
    14.9389  
Baker Brothers Life Sciences, L.P.
8/13/2010
    38,494  
Purchase
    14.8475  
14159, L.P.
8/13/2010
    1,063  
Purchase
    14.8475  
Baker Brothers Life Sciences, L.P.
8/13/2010
    8,914  
Purchase
    14.8070  
14159, L.P.
8/13/2010
    246  
Purchase
    14.8070  

 
Page 5 of 8 Pages

 
Item 6.
Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
 
Except as reported herein, neither of the Reporting Persons has any express contracts, arrangements or understandings with any other Reporting Person with respect to the securities of the Company.  Except as set forth in Item 7 below, none of the Reporting Persons has any contracts, arrangements, understandings or relationships with the Company.
 
Item 7.
Material to Be Filed as Exhibits.
 
Exhibit 1.
Agreement regarding the joint filing of this statement.
 

Page 6 of 8 Pages

 
 
SIGNATURE
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
August 13, 2010

                By:  /s/ Julian C. Baker        
                        Julian C. Baker

                By:  /s/ Felix J. Baker         
                       Felix J. Baker

Page 7 of 8 Pages


EXHIBIT 1

AGREEMENT
 
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.0001 par value, of Genomic Health, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
 
August 13, 2010

                By:  /s/ Julian C. Baker        
                        Julian C. Baker

                By:  /s/ Felix J. Baker         
                       Felix J. Baker

 
Page 8 of 8 Pages


-----END PRIVACY-ENHANCED MESSAGE-----